A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

Clinical trial NCT05121103 · TERMINATED

Trial details

NCT number: NCT05121103
Sponsor: Epizyme, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma, Refractory Diffuse Large B-Cell Lymphoma Diffuse Large B Cell Lymphoma Refractory Multiple Myeloma in Relapse

Start date: 2022-05-31
Primary completion: 2024-04-30
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.